Courses - Non-clinical safety evaluation, René Verloes (Tibotec) - In vitro and in vivo mutagenicity studies, Véronique Thybaud (Sanofi-Aventis) - Safety evaluation of anticancer drugs, biotechnology products and gene therapy agents, Philippe Detilleux (Sanofi-Aventis) - Cardiac safety assessment in drug development, Koen Van Rossem (Stiefel Laboratories) - Toxicogenomics and in silico evaluation of toxicity, Stéphane Dhalluin (UCB Pharma) - Drug design: influence of stereochemistry on biological activity and metabolism, François Dufrasne (ULB) - Drug formulation, Jonathan Goole (ULB) - Accelerating the move to clinical trials, Luc Tritsmans (J & J) - How to choose the dose for first in human administration, Luc Van Bortel (RUG) - New concepts at the boundary between preclinical and clinical research: phase 0, microdosing and exploratory trials, Jan de Hoon (KUL) - From pharmaceutical development to pharmaceutical manufacturing, Michel Deleers (Oncobel)
Understanding of: - Molecular and cellular basis of toxic reactions - Steps in the pharmaceutical development of a drug substance and final drug product - Early exploratory development in man
- Chemistry - Production technologies